Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Psychopharmacology Pub Date : 2022-07-30 eCollection Date: 2022-01-01 DOI:10.1177/20451253221113238
Yun Tien, Hsiang-Ping Huang, Ding-Lieh Liao, Shang-Chien Huang
{"title":"Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan.","authors":"Yun Tien,&nbsp;Hsiang-Ping Huang,&nbsp;Ding-Lieh Liao,&nbsp;Shang-Chien Huang","doi":"10.1177/20451253221113238","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripiprazole to be 100 to 350 ng/ml; however, most of these studies examined a Western population. Patients with schizophrenia from Tungs' Taichung MetroHarbor Hospital in central Taiwan were recruited to analyze the dose-response relationship of aripiprazole in the Chinese population.</p><p><strong>Objective: </strong>We aimed to investigate whether a serum concentration of aripiprazole higher than the current suggested range leads to higher response rates.</p><p><strong>Design: </strong>A prospective cohort study was designed to investigate the response rates in different studied cohorts grouped by serum concentration of aripiprazole.</p><p><strong>Data sources and methods: </strong>Data of 64 patients who presented to a single medical center in central Taiwan and who received therapeutic drug monitoring (TDM) were obtained. Serum concentrations of aripiprazole were correlated with the clinical response of patients by using the Clinical Global Impressions (CGI) scores.</p><p><strong>Results: </strong>The mean concentration of aripiprazole was 432.1 ± 275.1 ng/ml in the study cohort. Among the much-improved patients, the mean serum concentration of aripiprazole was 494 ± 273 ng/ml (25th-75th percentiles 264-666 ng/ml), which was higher than the current recommended therapeutic target of 100-350 ng/ml for aripiprazole. The response rate in the severe group (baseline CGI score of 6 or 7) was significantly higher than in the moderate group (baseline CGI score of 4 or 5; 86.7% <i>versus</i> 55.9%, <i>p</i> = 0.007).</p><p><strong>Conclusion: </strong>A significantly higher response rate was observed in the study cohort with serum aripiprazole concentrations over 300 ng/ml. Therefore, dosing higher than the current recommended range may potentially improve the treatment efficacy in the Chinese population. Because the serum concentration varies among patients due to multiple intrinsic and extrinsic factors, TDM, especially in outpatients, is recommended if the clinical response is limited.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/52/10.1177_20451253221113238.PMC9340887.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253221113238","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripiprazole to be 100 to 350 ng/ml; however, most of these studies examined a Western population. Patients with schizophrenia from Tungs' Taichung MetroHarbor Hospital in central Taiwan were recruited to analyze the dose-response relationship of aripiprazole in the Chinese population.

Objective: We aimed to investigate whether a serum concentration of aripiprazole higher than the current suggested range leads to higher response rates.

Design: A prospective cohort study was designed to investigate the response rates in different studied cohorts grouped by serum concentration of aripiprazole.

Data sources and methods: Data of 64 patients who presented to a single medical center in central Taiwan and who received therapeutic drug monitoring (TDM) were obtained. Serum concentrations of aripiprazole were correlated with the clinical response of patients by using the Clinical Global Impressions (CGI) scores.

Results: The mean concentration of aripiprazole was 432.1 ± 275.1 ng/ml in the study cohort. Among the much-improved patients, the mean serum concentration of aripiprazole was 494 ± 273 ng/ml (25th-75th percentiles 264-666 ng/ml), which was higher than the current recommended therapeutic target of 100-350 ng/ml for aripiprazole. The response rate in the severe group (baseline CGI score of 6 or 7) was significantly higher than in the moderate group (baseline CGI score of 4 or 5; 86.7% versus 55.9%, p = 0.007).

Conclusion: A significantly higher response rate was observed in the study cohort with serum aripiprazole concentrations over 300 ng/ml. Therefore, dosing higher than the current recommended range may potentially improve the treatment efficacy in the Chinese population. Because the serum concentration varies among patients due to multiple intrinsic and extrinsic factors, TDM, especially in outpatients, is recommended if the clinical response is limited.

Abstract Image

Abstract Image

Abstract Image

阿立哌唑对台湾精神分裂症患者的剂量-反应分析。
背景:阿立哌唑是第三代抗精神病药物,具有可接受的疗效和良好的安全性。既往研究表明阿立哌唑治疗性血清浓度为100 ~ 350 ng/ml;然而,这些研究大多是针对西方人群的。本研究从台湾中部的台中港大都会医院招募精神分裂症患者,分析阿立哌唑在中国人群中的剂量-反应关系。目的:我们的目的是研究阿立哌唑的血清浓度是否高于目前建议的范围导致更高的应答率。设计:设计一项前瞻性队列研究,以阿立哌唑的血清浓度为分组,调查不同研究队列的应答率。资料来源与方法:收集台湾中部单一医疗中心接受治疗药物监测(TDM)的64例患者资料。使用临床总体印象(CGI)评分将阿立哌唑的血清浓度与患者的临床反应相关联。结果:研究队列中阿立哌唑平均浓度为432.1±275.1 ng/ml。在病情好转的患者中,阿立哌唑的平均血清浓度为494±273 ng/ml(25 -75百分位数264-666 ng/ml),高于目前推荐的阿立哌唑治疗目标100-350 ng/ml。重度组(基线CGI评分为6或7分)的有效率显著高于中度组(基线CGI评分为4或5分;86.7%对55.9%,p = 0.007)。结论:血清阿立哌唑浓度超过300 ng/ml的研究队列应答率显著提高。因此,高于目前推荐范围的剂量可能会潜在地改善中国人群的治疗效果。由于患者的血清浓度因多种内在和外在因素而存在差异,因此在临床反应有限的情况下,推荐使用TDM,尤其是门诊患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信